APRE
HealthcareAprea Therapeutics, Inc.
$0.73-0.04 (-5.15%)
Prev Close
$0.77
Open
$0.77
High
$0.77
Low
$0.72
Volume
118.2K
Market Cap
$5.4M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Aprea Therapeutics, Inc. (APRE) has been exclusively buying, with 6 insider purchases totaling $76.1K and 0 insider sales totaling $0.00. The most recent insider transaction was by Hamill John P. (officer: SrVP/CFO/Prin Fin & Acct Ofcr), who purchased $5.1K worth of shares on Feb 2, 2026. Aprea Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $5.4M.
Buys (12M)
6
$76.1K
Sells (12M)
0
$0.00
Net Activity
Net Buyer
$76.1K
Active Insiders
3
last 12 mo
APRE Price Chart
APRE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026↗ | Hamill John P. | officer: SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,700 | $0.89 | $5.1K | 33,433 |
| Jan 30, 2026↗ | Gilad Oren | President/CEO | Buy | 28,100 | $0.89 | $25.0K | 0 |
| Jan 30, 2026↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,700 | $0.89 | $5.1K | 0 |
| Dec 10, 2025↗ | Duey Marc | Director | Buy | 21,459 | $1.16 | $25.0K | 0 |
| Dec 10, 2025↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,000 | $1.17 | $5.8K | 0 |
| Apr 3, 2025↗ | Gilad Oren | President/CEO | Buy | 5,500 | $1.84 | $10.1K | 0 |
| Oct 23, 2024↗ | Gilad Oren | President/CEO | Buy | 500 | $3.92 | $2.0K | 0 |
| Oct 18, 2024↗ | Duey Marc | Director | Sell | 6,462 | $4.58 | $29.6K | 0 |
| Oct 16, 2024↗ | Duey Marc | Director | Buy | 30,000 | $4.39 | $131.7K | 0 |
| Oct 15, 2024↗ | Gilad Oren | President/CEO | Buy | 250 | $2.90 | $725.00 | 0 |
| Oct 14, 2024↗ | Duey Marc | Director | Buy | 190 | $2.58 | $490.20 | 0 |
| Oct 11, 2024↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 50 | $2.46 | $123.19 | 0 |
| Oct 11, 2024↗ | Seizinger Bernd R. | Director | Buy | 10,000 | $2.68 | $26.8K | 0 |
| Oct 10, 2024↗ | Gilad Oren | President/CEO | Buy | 1,150 | $2.58 | $3.0K | 0 |
| Oct 10, 2024↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 450 | $2.61 | $1.2K | 0 |
| Mar 13, 2024↗ | Gilad Oren | President, CEO | Buy | 2,000 | $7.29 | $14.6K | 0 |
| Mar 13, 2024↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 1,010 | $7.29 | $7.4K | 0 |
| Mar 13, 2024↗ | HENNEMAN JOHN B III | Director | Buy | 6,860 | $7.29 | $50.0K | 0 |
| Mar 13, 2024↗ | Seizinger Bernd R. | Director | Buy | 6,860 | $7.29 | $50.0K | 0 |
| Jun 6, 2023↗ | Seizinger Bernd R. | Director | Buy | 10,097 | $3.66 | $37.0K | 0 |
| Jun 3, 2022↗ | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 32,667 | $0.80 | $26.3K | 0 |
| Jun 3, 2022↗ | Coiante Scott M | SVP, Chief Financial Officer | Sell | 35,284 | $0.80 | $28.4K | 0 |
| Jun 3, 2022↗ | Korbel Gregory Alan | SVP, Chief Operating Officer | Sell | 8,390 | $0.81 | $6.8K | 0 |
| Jun 3, 2022↗ | SCHADE CHRISTIAN S | Chairman & CEO | Sell | 65,770 | $0.81 | $52.9K | 0 |
| May 18, 2022↗ | SCHADE CHRISTIAN S | Chairman & CEO | Buy | 37,500 | $0.64 | $24.1K | 0 |
| May 18, 2022↗ | Seizinger Bernd R. | Director | Buy | 50,000 | $0.71 | $35.5K | 0 |
| Mar 10, 2022↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 1,989 | $1.82 | $3.6K | 0 |
| Feb 28, 2022↗ | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 36,000 | $1.73 | $62.3K | 0 |
| Feb 25, 2022↗ | Coiante Scott M | SVP, Chief Financial Officer | Sell | 14,817 | $1.74 | $25.8K | 0 |
| Feb 25, 2022↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 1,326 | $1.74 | $2.3K | 0 |
| Feb 25, 2022↗ | SCHADE CHRISTIAN S | Chairman & CEO | Sell | 21,644 | $1.74 | $37.7K | 0 |
| Dec 1, 2021↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $3.96 | $108.9K | 0 |
| Nov 1, 2021↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $5.00 | $137.5K | 0 |
| Oct 1, 2021↗ | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 50,000 | $4.89 | $244.5K | 0 |
| Oct 1, 2021↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $4.89 | $134.5K | 0 |
| Sep 20, 2021↗ | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 25,000 | $4.97 | $124.3K | 0 |
| Sep 20, 2021↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 32,960 | $4.97 | $163.9K | 0 |
| Sep 16, 2021↗ | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 15,968 | $4.68 | $74.7K | 0 |
| Sep 10, 2021↗ | Korbel Gregory Alan | Chief Business Officer | Sell | 1,724 | $4.59 | $7.9K | 0 |
| Aug 25, 2021↗ | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 9,032 | $3.98 | $35.9K | 0 |
| Aug 25, 2021↗ | Coiante Scott M | SVP, Chief Financial Officer | Sell | 7,534 | $3.98 | $30.0K | 0 |
| Aug 25, 2021↗ | Korbel Gregory Alan | Chief Business Officer | Sell | 1,149 | $3.98 | $4.6K | 0 |
APRE Insider Buying Activity
The following table shows recent insider purchases of Aprea Therapeutics, Inc. (APRE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026↗ | Hamill John P. | officer: SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,700 | $0.89 | $5.1K | 33,433 |
| Jan 30, 2026↗ | Gilad Oren | President/CEO | Buy | 28,100 | $0.89 | $25.0K | 0 |
| Jan 30, 2026↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,700 | $0.89 | $5.1K | 0 |
| Dec 10, 2025↗ | Duey Marc | Director | Buy | 21,459 | $1.16 | $25.0K | 0 |
| Dec 10, 2025↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,000 | $1.17 | $5.8K | 0 |
| Apr 3, 2025↗ | Gilad Oren | President/CEO | Buy | 5,500 | $1.84 | $10.1K | 0 |
| Oct 23, 2024↗ | Gilad Oren | President/CEO | Buy | 500 | $3.92 | $2.0K | 0 |
| Oct 16, 2024↗ | Duey Marc | Director | Buy | 30,000 | $4.39 | $131.7K | 0 |
| Oct 15, 2024↗ | Gilad Oren | President/CEO | Buy | 250 | $2.90 | $725.00 | 0 |
| Oct 14, 2024↗ | Duey Marc | Director | Buy | 190 | $2.58 | $490.20 | 0 |
| Oct 11, 2024↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 50 | $2.46 | $123.19 | 0 |
| Oct 11, 2024↗ | Seizinger Bernd R. | Director | Buy | 10,000 | $2.68 | $26.8K | 0 |
| Oct 10, 2024↗ | Gilad Oren | President/CEO | Buy | 1,150 | $2.58 | $3.0K | 0 |
| Oct 10, 2024↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 450 | $2.61 | $1.2K | 0 |
| Mar 13, 2024↗ | Gilad Oren | President, CEO | Buy | 2,000 | $7.29 | $14.6K | 0 |
| Mar 13, 2024↗ | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 1,010 | $7.29 | $7.4K | 0 |
| Mar 13, 2024↗ | HENNEMAN JOHN B III | Director | Buy | 6,860 | $7.29 | $50.0K | 0 |
| Mar 13, 2024↗ | Seizinger Bernd R. | Director | Buy | 6,860 | $7.29 | $50.0K | 0 |
| Jun 6, 2023↗ | Seizinger Bernd R. | Director | Buy | 10,097 | $3.66 | $37.0K | 0 |
| May 18, 2022↗ | SCHADE CHRISTIAN S | Chairman & CEO | Buy | 37,500 | $0.64 | $24.1K | 0 |
| May 18, 2022↗ | Seizinger Bernd R. | Director | Buy | 50,000 | $0.71 | $35.5K | 0 |
APRE Insider Selling Activity
The following table shows recent insider sales of Aprea Therapeutics, Inc. (APRE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 18, 2024↗ | Duey Marc | Director | Sell | 6,462 | $4.58 | $29.6K | 0 |
| Jun 3, 2022↗ | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 32,667 | $0.80 | $26.3K | 0 |
| Jun 3, 2022↗ | Coiante Scott M | SVP, Chief Financial Officer | Sell | 35,284 | $0.80 | $28.4K | 0 |
| Jun 3, 2022↗ | Korbel Gregory Alan | SVP, Chief Operating Officer | Sell | 8,390 | $0.81 | $6.8K | 0 |
| Jun 3, 2022↗ | SCHADE CHRISTIAN S | Chairman & CEO | Sell | 65,770 | $0.81 | $52.9K | 0 |
| Mar 10, 2022↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 1,989 | $1.82 | $3.6K | 0 |
| Feb 28, 2022↗ | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 36,000 | $1.73 | $62.3K | 0 |
| Feb 25, 2022↗ | Coiante Scott M | SVP, Chief Financial Officer | Sell | 14,817 | $1.74 | $25.8K | 0 |
| Feb 25, 2022↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 1,326 | $1.74 | $2.3K | 0 |
| Feb 25, 2022↗ | SCHADE CHRISTIAN S | Chairman & CEO | Sell | 21,644 | $1.74 | $37.7K | 0 |
| Dec 1, 2021↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $3.96 | $108.9K | 0 |
| Nov 1, 2021↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $5.00 | $137.5K | 0 |
| Oct 1, 2021↗ | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 50,000 | $4.89 | $244.5K | 0 |
| Oct 1, 2021↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $4.89 | $134.5K | 0 |
| Sep 20, 2021↗ | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 25,000 | $4.97 | $124.3K | 0 |
| Sep 20, 2021↗ | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 32,960 | $4.97 | $163.9K | 0 |
| Sep 16, 2021↗ | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 15,968 | $4.68 | $74.7K | 0 |
| Sep 10, 2021↗ | Korbel Gregory Alan | Chief Business Officer | Sell | 1,724 | $4.59 | $7.9K | 0 |
| Aug 25, 2021↗ | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 9,032 | $3.98 | $35.9K | 0 |
| Aug 25, 2021↗ | Coiante Scott M | SVP, Chief Financial Officer | Sell | 7,534 | $3.98 | $30.0K | 0 |
| Aug 25, 2021↗ | Korbel Gregory Alan | Chief Business Officer | Sell | 1,149 | $3.98 | $4.6K | 0 |
APRE Insiders
Similar Stocks to APRE
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B